Abstracts tagged "Quality of care and rheumatoid arthritis"

Abstract Number: 2493 • 2015 ACR/ARHP Annual Meeting
Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care
Pedro Ivan Santos-Moreno¹, Ginna Saavedra², Rosana Ramirez², Laura Villarreal², Ana Bolena Cardozo², Vanessa Giraldo², Paola Martinez², Adriana Sanchez², Merle Sanchez², Danny Gomez² and Juan Manuel Bello², ¹Rheumatology, Biomab, Center for Rheumatoid Arthritis., Bogota, Colombia, ²Rheumatology, Biomab, Center for Rheumatoid Arthritis, Bogota, Colombia, Bogota, Colombia
Background/Purpose: Treat to Target (T2T) strategy becomes from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA). Moreover,…
Abstract Number: 2510 • 2012 ACR/ARHP Annual Meeting
Patient and Provider Factors Associated with Compliance with Rheumatoid Arthritis Treatment Recommendations
Leslie R. Harrold¹, George W. Reed², Katherine C. Saunders³, Ying Shan¹, Tanya Spruill⁴ and Jeffrey D. Greenberg⁵, ¹Dept of Medicine, UMass Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Center for Healthful Behavior Change, Department of Population Health, NYU School of Medicine, New York, NY, ⁵New York Hospital for Joint Disease, New York, NY
Background/Purpose: Only approximately 50% of rheumatoid arthritis (RA) patient with active disease receive care consistent with the American College of Rheumatology (ACR) recommendations for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].